HIF‑1α in myocardial ischemia‑reperfusion injury (Review)

Mol Med Rep. 2021 May;23(5):352. doi: 10.3892/mmr.2021.11991. Epub 2021 Mar 24.

Abstract

Myocardial ischemia‑reperfusion injury (MIRI) is a severe injury to the ischemic myocardium following the recovery of blood flow. Currently, there is no effective treatment for MIRI in clinical practice. Over the past two decades, biological studies of hypoxia and hypoxia‑inducible factor‑1α (HIF‑1α) have notably improved understanding of oxygen homeostasis. HIF‑1α is an oxygen‑sensitive transcription factor that mediates adaptive metabolic responses to hypoxia and serves a pivotal role in MIRI. In particular, previous studies have demonstrated that HIF‑1α improves mitochondrial function, decreases cellular oxidative stress, activates cardioprotective signaling pathways and downstream protective genes and interacts with non‑coding RNAs. The present review summarizes the roles and associated mechanisms of action of HIF‑1α in MIRI. In addition, HIF‑1α‑associated MIRI intervention, including natural compounds, exosomes, ischemic preconditioning and ischemic post‑processing are presented. The present review provides evidence for the roles of HIF‑1α activation in MIRI and supports its use as a therapeutic target.

Keywords: hypoxia‑inducible factor‑1α; ischemic heart disease; myocardial ischemia‑reperfusion injury; mitochondrial function.

Publication types

  • Review

MeSH terms

  • Apoptosis / genetics
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit / genetics*
  • Ischemic Preconditioning
  • Mitochondria / genetics
  • Myocardial Reperfusion Injury / genetics*
  • Myocardial Reperfusion Injury / pathology
  • Reperfusion Injury / genetics*
  • Reperfusion Injury / pathology
  • Signal Transduction / genetics

Substances

  • HIF1A protein, human
  • Hypoxia-Inducible Factor 1, alpha Subunit

Grants and funding

The present paper was supported by the National Natural Science Foundation of China (grant no. 81700269).